Ketamine Enhances Approach-Avoidance Decision-Making in Healthy Adults
A Freiburg randomized crossover study finds intranasal ketamine improves value-driven conflict resolution compared to lorazepam, informing future research on mood disorder treatments.
Ketamine Improves Strategic Approach-Avoidance Behavior in Healthy Adults
In a randomized crossover study published on November 20, 2026 (OpenAlex W7237017152), researchers at the University Medical Center Freiburg (German Clinical Trials Register DRKS00025471) found that intranasal ketamine significantly enhances efficient, value-driven approach-avoidance conflict resolution in healthy participants compared to both a control condition and lorazepam. This direct comparison provides rare mechanistic insight into ketamine's unique effects on adaptive decision-making, a process often disrupted in depression and anxiety disorders.
Mechanistic Insights: Ketamine vs. Lorazepam in Motivational Flexibility
Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, was compared head-to-head with lorazepam, a benzodiazepine known for dampening neural excitability. In this study, 34 healthy adults completed three sessions—control, intranasal ketamine (50 mg), and oral lorazepam (1 mg)—in randomized, counterbalanced order. The core task assessed participants' ability to balance approach and avoidance in a dynamic conflict scenario, with varying threat probabilities and loss magnitudes. Behavioral outcomes included net token gain, approach behavior, and response latencies.
Ketamine administration led to a 57% higher token gain versus control and a 33% improvement over lorazepam, with behavior more closely guided by outcome value than by threat probability. Participants also demonstrated faster approach and withdrawal responses after ketamine. In contrast, lorazepam produced a less selective increase in approach behavior, suggesting a blunter, less strategic effect on motivational processes. Notably, the study controlled for acute dissociative effects by timing the task after ketamine's peak subjective effects had subsided.
Policy and Research Implications: Informing Future Clinical Trials
These findings provide mechanistic support for ketamine's potential in treating disorders characterized by maladaptive avoidance, such as major depressive disorder (MDD) and anxiety disorders. While the study was limited to healthy volunteers, the robust, value-sensitive behavioral improvements observed with ketamine—but not lorazepam—suggest a distinct pharmacological pathway that could be leveraged in clinical populations. This distinction is critical for future trial design: while benzodiazepines have long been used for anxiety, their broad dampening of neural activity may not support strategic, adaptive behavior in the same way as ketamine.
For policymakers and research sponsors, the study underscores the need for trials that move beyond symptom checklists and directly assess decision-making flexibility in patient populations. The use of dynamic, ecologically valid behavioral tasks in this study sets a new bar for mechanistic rigor in early-phase psychedelic research. In addition, the head-to-head design with lorazepam provides a more clinically relevant comparator than placebo alone, sharpening the translational value of the findings.
Risks, Limitations, and Unknowns
The immediate safety profile in this small, healthy sample was favorable, with no unexpected adverse events reported. However, the trial's exclusion of individuals with psychiatric or neurological disorders means the results cannot be generalized to clinical populations without further study. The study's single-dose, acute design also leaves open questions about the durability of ketamine's effects on approach-avoidance behavior and whether repeated dosing or integration with psychotherapy would yield sustained benefits.
Another limitation is the lack of participant and physician blinding, which could introduce expectancy effects, although behavioral assessors were blinded to condition. Furthermore, while the task captures key elements of real-world decision-making, it remains a laboratory measure; translation to functional outcomes in daily life is not assured. Finally, the potential for misuse, dissociation, or other adverse effects with repeated ketamine administration remains a critical area for ongoing monitoring and risk mitigation.
Looking Forward: Next Steps for Mechanistic and Clinical Research
The Freiburg study adds a crucial piece of evidence to the evolving understanding of ketamine's neurobehavioral effects, highlighting its capacity to enhance strategic, value-driven decision-making. For the field, this suggests a pathway for developing more targeted interventions for mood and anxiety disorders—ones that address the core cognitive and motivational deficits underlying chronic avoidance. Future studies should prioritize patient samples, longer-term follow-up, and integration with psychotherapeutic strategies to assess real-world impact and safety. Notably, the use of active comparators like lorazepam in early-phase trials may become a new standard, ensuring that novel treatments are not only effective but also meaningfully distinct from existing options.
Authored by Dr. Alex R. Meyer, PhD (Neuroscience, University of Freiburg). Reviewed by Dr. Lena Hoffmann, MD, on 2026-11-22. Research based on primary publication and trial registry sources.
Get tomorrow's briefing in your inbox
Policy, research, and regulatory signal — delivered on our publish cadence.